Related references
Note: Only part of the references are listed.Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
T. Powles
ANNALS OF ONCOLOGY (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Adi Diab et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
Meenu Sharma et al.
NATURE COMMUNICATIONS (2020)
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab et al.
CANCER DISCOVERY (2020)
The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review
Shouki Bazarbashi et al.
FUTURE ONCOLOGY (2020)
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Roles of IFN-γ in tumor progression and regression: a review
Dragica Jorgovanovic et al.
BIOMARKER RESEARCH (2020)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges et al.
ESMO OPEN (2020)
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
Matthew K. Labriola et al.
CLINICAL GENITOURINARY CANCER (2019)
NKTR-214+nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
Arlene O. Siefker-Radtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry
M. Fishman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel et al.
CANCER DISCOVERY (2019)
The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
Alessandra Raimondi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
Michael B. Atkins et al.
CANCER TREATMENT REVIEWS (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Biomarkers for Clinical Benefit of immune Checkpoint inhibitor Treatment-A Review From the Melanoma Perspective and Beyond
Kristina Buder-Bakhaya et al.
FRONTIERS IN IMMUNOLOGY (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
871PKEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)
F Donskov et al.
ANNALS OF ONCOLOGY (2018)
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry
Brendan Curti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
Deborah Charych et al.
PLOS ONE (2017)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P. Dutcher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Share Paper
